1. Show article details.

    BRIEF-FibroGen Completes Patient Enrollment In Phase 3 Study Of Duchenne Muscular Dystrophy Treatment

    Reuters – 8:45 AM ET 06/08/2022

    FibroGen Inc (FGEN): * FIBROGEN ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN LELANTOS-2, A PHASE 3 CLINICAL STUDY OF PAMREVLUMAB IN DUCHENNE MUSCULAR DYSTROPHY. * FibroGen Inc (FGEN) - TOP-LINE DATA FROM LELANTOS-2 STUDY IS ANTICIPATED IN 2H:2023 Source text for Eikon: Further company coverage:

  2. Show article details.

    FibroGen Announces Completion of Patient Enrollment in LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Duchenne Muscular Dystrophy

    GlobeNewswire – 7:00 AM ET 06/08/2022

    - 73 Ambulatory DMD Patients Enrolled -- Topline Data Anticipated 2H:2023 - FibroGen (FGEN), Inc.  today announced completion of patient enrollment for LELANTOS-2, a Phase 3 clinical study of pamrevlumab in patients with ambulatory Duchenne muscular dystrophy.

  3. Show article details.

    FIBROGEN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of FibroGen, Inc. - FGEN

    Business Wire – 10:50 PM ET 05/27/2022

    Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC, announces that KSF continues its investigation into FibroGen, Inc. (FGEN). On April 6, 2021, the Company disclosed that cardiovascular safety data it had previously submitted for the Phase 3 program of its roxadustat product “included post-hoc changes to the stratification factors.

  4. Show article details.

    FibroGen to Present at Jefferies Healthcare Conference

    GlobeNewswire – 7:00 AM ET 05/26/2022

    FibroGen, Inc. (FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9 at 1:30pm EDT. A live audio webcast of the event will be available on the “Events & Presentations” section of the FibroGen Investors webpage at www.fibrogen.com. A replay will be available for approximately 30 days.

  5. Show article details.

    FIBROGEN INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of FibroGen, Inc. - FGEN

    PR Newswire – 10:50 PM ET 05/13/2022

    NEW ORLEANS, May 13, 2022 Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC, announces that KSF continues its investigation into FibroGen (FGEN), Inc..

  6. Show article details.

    103 Biggest Movers From Yesterday

    Benzinga – 6:22 AM ET 05/11/2022

    103 Biggest Movers From Yesterday

  7. Show article details.

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    Benzinga – 1:48 PM ET 05/10/2022

      This article was generated by Benzinga's automated content engine and reviewed by an editor.

  8. Show article details.

    77 Stocks Moving In Tuesday's Mid-Day Session

    Benzinga – 12:00 PM ET 05/10/2022

             

  9. Show article details.

    BRIEF-FibroGen Q1 Loss Per Share $0.68

    Reuters – 5:13 PM ET 05/09/2022

    FibroGen Inc (FGEN): * FIBROGEN REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS. * Q1 REVENUE ROSE 58 PERCENT TO $60.8 MILLION. * Q1 LOSS PER SHARE $0.68. * Q1 EARNINGS PER SHARE VIEW $-0.83, REVENUE VIEW $28.8 MILLION -- REFINITIV IBES DATA Source text for Eikon: Further company coverage:

  10. Show article details.

    FibroGen Reports First Quarter 2022 Financial Results

    GlobeNewswire – 4:01 PM ET 05/09/2022

    SAN FRANCISCO, May 09, 2022 -- FibroGen, Inc. (FGEN) today reported financial results for the first quarter 2022 and provided an update on the company’s recent developments.

  11. Show article details.

    The Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru's Pre-EUA Meeting, Conference Presentations And More

    Benzinga – 8:33 AM ET 05/09/2022

    Biotech stocks declined yet again in the week ending May 6, dragged lower by macroeconomic concerns following the Federal Reserve's 50-basis-point rate hike. Penny stock and digital therapeutics company Better Therapeutics, Inc. more than doubled despite a lack of any meaningful catalysts. Earnings news flow also continued to move stocks in the space.

  12. Show article details.

    12 Health Care Stocks Moving In Monday's Pre-Market Session

    Benzinga – 8:18 AM ET 05/09/2022

      This article was generated by Benzinga's automated content engine and reviewed by an editor.

  13. Show article details.

    20 Stocks Moving in Monday's Pre-Market Session

    Benzinga – 7:08 AM ET 05/09/2022

    Don't forget to check out our premarket coverage here .

  14. Show article details.

    Earnings Scheduled For May 9, 2022

    Benzinga – 4:52 AM ET 05/09/2022

      ** Atlantica Sustainable is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million. ** NAPCO Security is estimated to report quarterly earnings at $0.07 per share on revenue of $34.66 million. ** GEO Group is projected to report quarterly earnings at $0.10 per share on revenue of $39.26 million.

  15. Show article details.

    Stocks That Hit 52-Week Lows On Friday

    Benzinga – 12:06 PM ET 05/06/2022

      On Friday, 1043 companies hit new 52-week lows. Stocks dropping to new 52-week lows on Friday: Be sure to monitor Benzinga for the news traders need!

  16. Show article details.

    Earnings Outlook For FibroGen

    Benzinga – 10:07 AM ET 05/06/2022

    FibroGen is set to give its latest quarterly earnings report on Monday, 2022-05-09. Analysts estimate that FibroGen will report an earnings per share of $-0.83. FibroGen bulls will hope to hear the company to announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

  17. Show article details.

    FIBROGEN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of FibroGen, Inc. - FGEN

    Business Wire – 3:17 PM ET 05/05/2022

    Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC, announces that KSF continues its investigation into FibroGen, Inc. (FGEN). On April 6, 2021, the Company disclosed that cardiovascular safety data it had previously submitted for the Phase 3 program of its roxadustat product “included post-hoc changes to the stratification factors.

  18. Show article details.

    FIBROGEN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of FibroGen, Inc. - FGEN

    Business Wire – 10:50 PM ET 04/29/2022

    Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC, announces that KSF has commenced an investigation into FibroGen, Inc. (FGEN). On April 6, 2021, the Company disclosed that cardiovascular safety data it had previously submitted for the Phase 3 program of its roxadustat product “included post-hoc changes to the stratification factors.

  19. Show article details.

    Stocks That Hit 52-Week Lows On Thursday

    Benzinga – 3:31 PM ET 04/28/2022

      During Thursday, 849 stocks hit new 52-week lows. During the morning session of trading on Thursday, the following stocks broke to new 52-week lows: Be sure to stay with Benzinga for further updates and market-moving news.

  20. Show article details.

    FibroGen to Report First Quarter 2022 Financial Results

    GlobeNewswire – 7:00 AM ET 04/25/2022

    FibroGen, Inc. (FGEN) will announce its first quarter 2022 financial results on Monday, May 9 after the market close. Conference Call and Audio Webcast Interested parties may access a live audio webcast of the conference call via the FibroGen (FGEN) website at https://fibrogen.gcs-web.com/events-and-presentations/events. Dial-In InformationLive: 658-9081Live: 563-8732Confirmation number: 2487763.

Page:

Today's and Upcoming Events

  • Aug
    08

    FGEN to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    09

    FGEN announced Q1 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.